Cystatin C is a useful predictor of early neurological deterioration following ischaemic stroke in elderly patients with normal renal function
- PMID: 31008299
- PMCID: PMC6453184
- DOI: 10.1177/2396987316677197
Cystatin C is a useful predictor of early neurological deterioration following ischaemic stroke in elderly patients with normal renal function
Abstract
Introduction: Cystatin C has been suggested as a sensitive marker of renal function. A high level of cystatin C is related to cardiovascular disease and stroke in elderly patients. We investigated the relationship between levels of cystatin C and early neurological deterioration with acute ischaemic stroke in elderly patients without chronic kidney disease.
Patients and methods: We evaluated a total of 771 elderly patients (mean age, 72.2; male, 59.0%) without chronic kidney disease who were admitted following acute ischaemic stroke between March 2010 and January 2015. The patients were divided into four groups based on the quartiles of serum cystatin C values. Early neurological deterioration was defined as an increase of ≥2 points from the baseline National Institutes of Health Stroke Scale score during the 7 days following onset. We compared the clinical characteristics and cystatin C concentrations between patients with and without early neurological deterioration.
Results: Eighty-six patients (11.2%) experienced early neurological deterioration. The percentage values of the higher (third and fourth) quartiles were significantly higher in the early neurological deterioration group (30.2% vs. 24.4% and 34.9% vs. 23.8%, P = 0.002). After adjustment for covariates, higher cystatin C levels were independently associated with a higher risk of early neurological deterioration: odds ratio (95% confidence interval) for second quartile 1.59 (0.70-3.58), third quartile 2.75 (1.25-6.04), fourth quartile 3.12 (1.36-7.16); P for trend 0.026.
Discussion and conclusions: This study demonstrated that cystatin C concentrations in elderly patients without chronic kidney disease were associated with early neurological deterioration following acute stroke. This suggests that cystatin C level could be a useful predictor for early neurological deterioration following acute stroke.
Keywords: Cystatin C; early neurological deterioration; elderly patients; normal renal function.
Conflict of interest statement
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures
Similar articles
-
A Systematic Review of Body Fluids Biomarkers Associated With Early Neurological Deterioration Following Acute Ischemic Stroke.Front Aging Neurosci. 2022 May 30;14:918473. doi: 10.3389/fnagi.2022.918473. eCollection 2022. Front Aging Neurosci. 2022. PMID: 35711907 Free PMC article. Review.
-
Monocyte to High-Density Lipoprotein Ratio Is Associated With Early Neurological Deterioration in Acute Isolated Pontine Infarction.Front Neurol. 2021 Jun 28;12:678884. doi: 10.3389/fneur.2021.678884. eCollection 2021. Front Neurol. 2021. PMID: 34262524 Free PMC article.
-
Elevated glucose level adversely affects infarct volume growth and neurological deterioration in non-diabetic stroke patients, but not diabetic stroke patients.Eur J Neurol. 2014 Mar;21(3):402-10. doi: 10.1111/ene.12280. Epub 2013 Nov 4. Eur J Neurol. 2014. PMID: 24517878
-
Cystatin C, associated with hemorrhagic and ischemic stroke, is a strong predictor of the risk of cardiovascular events and death in Chinese.Stroke. 2007 Dec;38(12):3287-8. doi: 10.1161/STROKEAHA.107.489625. Epub 2007 Oct 18. Stroke. 2007. PMID: 17947596
-
Serum cystatin C and increased coronary heart disease prevalence in US adults without chronic kidney disease.Am J Cardiol. 2008 Jul 1;102(1):54-7. doi: 10.1016/j.amjcard.2008.02.098. Epub 2008 May 2. Am J Cardiol. 2008. PMID: 18572035
Cited by
-
Blood pressure variability and early neurological deterioration according to the chronic kidney disease risk categories in minor ischemic stroke patients.PLoS One. 2022 Sep 7;17(9):e0274180. doi: 10.1371/journal.pone.0274180. eCollection 2022. PLoS One. 2022. PMID: 36070300 Free PMC article.
-
The Predictive Power of the Cystatin C-Creatinine Score in Assessing Frailty.J Cachexia Sarcopenia Muscle. 2025;16(4):e70040. doi: 10.1002/jcsm.70040. J Cachexia Sarcopenia Muscle. 2025. PMID: 40817389 Free PMC article.
-
A Systematic Review of Body Fluids Biomarkers Associated With Early Neurological Deterioration Following Acute Ischemic Stroke.Front Aging Neurosci. 2022 May 30;14:918473. doi: 10.3389/fnagi.2022.918473. eCollection 2022. Front Aging Neurosci. 2022. PMID: 35711907 Free PMC article. Review.
-
Prediction of Outcomes Through Cystatin C and cTnI in Elderly Type 2 Myocardial Infarction Patients.Clin Interv Aging. 2023 Aug 25;18:1415-1422. doi: 10.2147/CIA.S416372. eCollection 2023. Clin Interv Aging. 2023. PMID: 37649549 Free PMC article.
-
Association between serum cystatin C level and post-stroke cognitive impairment in patients with acute mild ischemic stroke.Brain Behav. 2022 Mar;12(3):e2519. doi: 10.1002/brb3.2519. Epub 2022 Feb 11. Brain Behav. 2022. PMID: 35148465 Free PMC article.
References
-
- Menon V, Shlipak MG, Wang X, et al. Cystatin c as a risk factor for outcomes in chronic kidney disease. Ann Int Med 2007; 147: 19–27. - PubMed
-
- Ledoux D, Monchi M, Chapelle J-P, et al. Cystatin c blood level as a risk factor for death after heart surgery. Eur Heart J 2007; 28: 1848–1853. - PubMed
-
- Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin c and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Int Med 2006; 145: 237–246. - PubMed
-
- Wu C-K, Lin J-W, Caffrey JL, et al. Cystatin c and long-term mortality among subjects with normal creatinine-based estimated glomerular filtration rates: Nhanes iii (third national health and nutrition examination survey). J Am Coll Cardiol 2010; 56: 1930–1936. - PubMed
LinkOut - more resources
Full Text Sources